CytoAgents
Private Company
Funding information not available
Overview
CytoAgents is pioneering a novel, steroid-sparing approach to modulate hyperactive immune responses that drive severe toxicities and limit the efficacy of transformative therapies. Its lead asset, CTO1681, is a prostaglandin/prostacyclin pathway inhibitor designed to safely dampen cytokine storms while preserving immune function, currently in Phase 1b/2a trials for CAR T-cell therapy-related inflammation. The company aims to expand into multiple inflammatory indications where viral or bacterial infections exacerbate disease, positioning CTO1681 as a potential foundational immunomodulator. Founded in 2016 and based in San Diego, CytoAgents is a private, pre-revenue company advancing its first-in-class oral therapy through clinical development.
Technology Platform
Oral small molecule inhibitors targeting the PGE2 and NF-κB signaling pathways to modulate prostaglandin/prostacyclin-mediated inflammation and cytokine amplification without broad immunosuppression.
Opportunities
Risk Factors
Competitive Landscape
Competition in CRS management includes approved IL-6 inhibitors (tocilizumab), IL-1 inhibitors, corticosteroids, and numerous investigational agents. In inflammatory diseases, competition is intense with biologics and JAK inhibitors. CytoAgents' differentiation hinges on its oral, steroid-sparing mechanism targeting upstream PGE2/NF-κB pathways.